
“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at dasatinib and exemestane for people with advanced breast cancer that is oestrogen receptor positive. The trial is looking at cancer that has come back or started to grow again after treatment with a type of hormone therapy called a non steroidal aromatase inhibitor.
Doctors treat oestrogen receptor positive breast cancer with hormone therapy. They often use drugs such as anastrozole or letrozole which are called non steroidal aromatase inhibitors. If breast cancer comes back or starts to grow again after this type of treatment, you may have another type of aromatase inhibitor called exemestane which is a steroidal aromatase inhibitor.
Dasatinib is a type of biological therapy called a tyrosine kinase inhibitor (TKI). It works by blocking chemical messengers called tyrosine kinases. Blocking these can stop cancer cells growing.
The aim of this study is to see if exemestane and dasatinib is better than exemestane alone for advanced oestrogen receptor positive breast cancer that has come back or started growing again after treatment with other aromatase inhibitors. And to learn more about the side effects.
You can enter this trial if
You cannot enter this trial if you
This is an international trial. It will recruit about 156 people in different countries. There will be about 12 people taking part in the UK. It is a randomised trial. The people taking part will be put into one of 2 treatment groups by computer. Neither you nor your doctor can decide which group you are in. And neither you nor your doctor will know which group you are in. This is called a double blind trial.
Both drugs are tablets that you take at home each day. As long as you don’t have bad side effects, you can carry on having the trial treatment for as long as it helps you.
You will see the trial doctors and have some tests before you start treatment. The tests include
You go to hospital on the first day of treatment, then after 2 weeks, 4 weeks and 8 weeks. After that you go every 8 weeks. Each visit will last between 1 and 4 hours.
You have a CT or MRI scan every 8 weeks. If you have breast cancer that has spread to your bones, you will also have a bone scan every 3 or 4 months.
When you finish treatment, you go back to see the trial doctor a month later and you may need to have another scan at this time.
If you leave the trial for any reason other than your breast cancer getting worse, the trial team will contact you every 2 months to see how you are. And you will have scans every 8 weeks until your cancer starts to grow again.
The side effects of dasatinib include
The side effects of exemestane include
There is more information about the side effects of dasatinib and exemestane on CancerHelp UK.
So far, most trials looking at dasatinib have been for people who have leukaemia. It is possible that some of the side effects may be less for people who have a solid tumour such as breast cancer. But the combination of dasatinib and exemestane has not been studied before. So it is also possible that some side effects, such as muscle or bone pain, diarrhoea, sickness, rash or headache could be worse when you have these 2 drugs together.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Christopher Poole
Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)
Freephone 0808 800 4040
“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."